First clinical multicenter experience of the new NeVa NET 5.5 thrombectomy device

Area of Science:

• Endovascular therapy
• Neurointerventional surgery
• Cerebrovascular disease

Background:

• Mechanical thrombectomy has improved, but distal emboli and incomplete reperfusion remain challenges in acute ischemic stroke.
• The NeVa NET 5.5 stent retriever is a novel device with an integrated micro-filtration system designed to improve first-pass efficacy and reduce distal embolization.

Purpose of the Study:

• To evaluate the safety and efficacy of the NeVa NET 5.5 stent retriever for acute ischemic stroke treatment.
• To assess the device's performance in achieving reperfusion and preventing distal embolization.

Main Methods:

• Retrospective study of 51 patients with acute anterior circulation occlusions treated with the NeVa NET 5.5 stent retriever.
• Data collected from three European stroke centers between October 2022 and April 2024.
• Analysis of patient data, occlusion details, clinical outcomes, and procedure-related parameters.

Main Results:

• High first-pass reperfusion (eTICI 2b-3) achieved in 78.5% of patients.
• Excellent final reperfusion rate (eTICI 2b-3) of 98.1%.
• Low rate of distal embolization (3.9%) and no device-related adverse events reported.

Conclusions:

• The NeVa NET 5.5 stent retriever demonstrates a high first-pass reperfusion rate for anterior circulation large vessel occlusions.
• The device offers a favorable safety profile with a low incidence of distal embolization.
• This technology shows promise in improving outcomes for endovascular stroke treatment.